GALWAY, IRELAND--January 22, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Buoyed by the runaway success of its diabetes and weight loss drugs Ozempic and Wegovy, Denmark's Novo Nordisk A/S (NYSE:NVO) (Bagsværd, Denmark) has plans to build a major manufacturing operation at its Grange Castle campus in Dublin, Ireland. Within this article: Details new plant investment in Dublin to boost production of Ozempic and Wegovy, scale, timeline, related European investments
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×For More Info!
